BioRestorative Therapies, Inc. (BRTX) Financial Statements
Industry: Misc Health & Allied Services (Other) (Services)
In fiscal 2025, BioRestorative Therapies reported revenue of $359,700, down 10.3% from $401,000 the year before. Net income was -$14.2M (a -3959.4% net margin), or -$31.60 per diluted share. Gross margin was 93.4% and operating margin was -4350.1%. Operating activities generated -$10.8M of cash, leaving -$10.9M of free cash flow. At fiscal year end, BioRestorative Therapies held $4.1M in total assets against $3.7M in total liabilities, including $1.5M of cash and equivalents.
Open the full interactive BioRestorative Therapies financials → Quarterly statements, key ratios, valuation history and price charts.
BioRestorative Therapies Key Stats
| Share Price | $1.59 |
|---|---|
| Market Cap | $1.4M |
| Revenue YoY Growth | -10.3% |
| 52-Week Range | $0.14 – $4.94 |
| Shares Outstanding | 886,387 (basic, 2026 Q1) |
BioRestorative Therapies Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $77,000 | $46,000 | $119,800 | $145,800 | $401,000 | $359,700 |
| Cost of Goods Sold | — | — | — | — | $28,072 | $23,844 |
| Gross Profit | — | — | — | — | $372,928 | $335,856 |
| Operating Income | -$2.8M | -$26.3M | -$19.0M | -$15.2M | -$11.6M | -$15.6M |
| Pre-Tax Income | -$11.3M | -$44.3M | -$18.5M | -$14.4M | -$9.0M | -$14.2M |
| Income Tax | — | — | — | — | — | $41,475 |
| Net Income | -$11.3M | -$44.3M | -$18.5M | -$14.4M | -$9.0M | -$14.2M |
| Diluted EPS | -$0.20 | -$746.00 | — | -$68.40 | -$23.20 | -$31.60 |
BioRestorative Therapies Quarterly Results
| 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | |
|---|---|---|---|---|
| Revenue | $303,300 | $11,800 | $19,600 | $23,170 |
| Net Income | -$2.7M | -$3.0M | -$3.2M | -$2.2M |
| Diluted EPS | -$6.00 | -$6.60 | -$0.36 | -$2.40 |
BioRestorative Therapies Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $1.7M | $884,377 | $547,890 | $1.5M |
| Current Assets | $3.2M | $21.5M | $15.1M | $11.4M | $11.1M | $3.1M |
| Total Assets | $4.3M | $22.5M | $16.4M | $12.6M | $12.3M | $4.1M |
| Current Liabilities | $1.0M | $363,822 | $440,302 | $1.1M | $3.7M | $3.7M |
| Total Long-Term Debt | $4.3M | $250,000 | — | — | — | — |
| Total Liabilities | $5.7M | $856,497 | $602,619 | $1.1M | $3.7M | $3.7M |
| Shareholders' Equity | -$1.3M | $21.6M | $15.8M | $11.5M | $8.5M | $356,744 |
BioRestorative Therapies Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$2.0M | -$3.3M | -$5.9M | -$6.4M | -$8.2M | -$10.8M |
| Cash From Investing | — | -$30,658 | -$13.5M | $3.3M | $514,529 | $8.9M |
| Cash From Financing | $5.5M | $21.3M | — | $2.4M | $7.4M | $2.9M |
| Free Cash Flow | -$2.0M | -$3.4M | -$6.1M | -$6.6M | -$8.3M | -$10.9M |
Figures from BioRestorative Therapies' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BioRestorative Therapies financials page for every line item.
BioRestorative Therapies Company Profile
| Ticker | BRTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Misc Health & Allied Services (Other) (Services) |
| Headquarters | Melville, New York |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001505497 |
Frequently Asked Questions
What was BioRestorative Therapies' revenue in fiscal 2025?
BioRestorative Therapies (BRTX) reported revenue of $359,700 for fiscal 2025.
What is BioRestorative Therapies' annual revenue history?
BioRestorative Therapies' annual revenue by fiscal year: 2020: $77,000; 2021: $46,000; 2022: $119,800; 2023: $145,800; 2024: $401,000; 2025: $359,700.
What was BioRestorative Therapies' net income in fiscal 2025?
BioRestorative Therapies reported net income of -$14.2M for fiscal 2025.
What was BioRestorative Therapies' earnings per share (EPS) in fiscal 2025?
BioRestorative Therapies' diluted EPS was -$31.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BioRestorative Therapies generate in fiscal 2025?
BioRestorative Therapies generated -$10.9M of free cash flow in fiscal 2025.
What was BioRestorative Therapies' revenue last quarter?
In its most recent reported quarter (2026 Q1), BioRestorative Therapies reported revenue of $23,170.
How many shares of BioRestorative Therapies are outstanding?
BioRestorative Therapies reported a weighted average of 886,387 basic shares outstanding in 2026 Q1.
What is BioRestorative Therapies' market cap?
Based on its latest closing price, BioRestorative Therapies (BRTX) has a market capitalization of about $1.4M.
When does BioRestorative Therapies' fiscal year end?
BioRestorative Therapies' fiscal year end, as registered with the SEC, is December 31.
Where is BioRestorative Therapies headquartered?
BioRestorative Therapies lists its business address in Melville, New York in its SEC filings.
BioRestorative Therapies Competitors & Similar Companies
See all 9 Misc Health & Allied Services (Other) (Services) companies →